Fig. 3

Forest plots of the pooled HRs for the OS of the patients with MM in the MAbs targeting CD38 (including daratumumab) and SLAMF7 (including elotuzumab) groups versus their corresponding control groups. The HR < 1 favours the MAb group. The size of the blocks or diamonds represents the weight of the fixed effects model in the meta-analysis